Kosuke Kashiwabara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kosuke Kashiwabara has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Shinsuke Tsumura
Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan
19 shared publicationsShinji Fujii
Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan
18 shared publicationsHiroshi Semba
Department of Respiratory Medicine, Kumamoto Regional Medical Center, Honjo, Japan
10 shared publicationsKazuhiko Sakamoto
Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan
10 shared publicationsFujiho Tanaka
Department of Respiratory Medicine, Omotesando Yoshida Hospital, Kumamoto, Japan
2 shared publications- Isamu Okamoto
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer
Matsunaga A, et al. J Gynecol Oncol. 2026 ;37:e99. https://doi.org/10.3802/jgo.2026.37.e99
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Open AccessType-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer
Matsunaga A, et al. J Gynecol Oncol. 2026 ;37:e99. https://doi.org/10.3802/jgo.2026.37.e99
- 4 October 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (5) , 1-8
Clinical predictors of underlying severe obstructive sleep apnea in patients undergoing gastrointestinal endoscopy under conscious sedation
Background Of patients suspected as having obstructive sleep apnea (OSA) while undergoing routine gastrointestinal endoscopy under conscious sedation (GE-CS), 43% have severe disease but have never consulted specialist clinics because of the absence of significant symptoms/signs. If patients with possible severe OSA can be predicted during GE-CS, they could be advised to consult sleep specialist clinics. Materials and Methods We retrospectively analyzed data of 112 patients who were suspected as having OSA during GE-CS and underwent sleep apnea testing at our hospital, to evaluate whether patient characteristics, endoscopic detection of upper airway obstruction (UAO), and vital signs during routine GE-CS can predict the possibility of severe underlying OSA. Results The mean age of the patients was 55 years, 74% were men, and 64% had obesity. Severe OSA was diagnosed in 13% of patients with mild UAO (< 50% luminal stenosis), 18% of patients with moderate UAO (50%-75% stenosis), and 45% of patients with severe UAO (> 75% stenosis). The UAO severity was positively correlated with the apnea hypopnea index score (r = 0.305, p = 0.001) and negatively correlated with the minimum SpO2 during GE-CS (r = 0.285, p = 0.023). Logistic regression analysis identified male gender (HR 4.19, p = 0.0267), severe UAO (HR 3.69, p = 0.009), and minimum SpO2 < 90% during GE-CS (HR 3.82, p = 0.008) as an independent predictors of severe OSA. Conclusion Not only the presence of UAO, but also minimum SpO2 < 90% during GE-CS was identified as an independent predictor of severe OSA.
- 4 October 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (5) , 1-8
Clinical predictors of underlying severe obstructive sleep apnea in patients undergoing gastrointestinal endoscopy under conscious sedation
Background Of patients suspected as having obstructive sleep apnea (OSA) while undergoing routine gastrointestinal endoscopy under conscious sedation (GE-CS), 43% have severe disease but have never consulted specialist clinics because of the absence of significant symptoms/signs. If patients with possible severe OSA can be predicted during GE-CS, they could be advised to consult sleep specialist clinics. Materials and Methods We retrospectively analyzed data of 112 patients who were suspected as having OSA during GE-CS and underwent sleep apnea testing at our hospital, to evaluate whether patient characteristics, endoscopic detection of upper airway obstruction (UAO), and vital signs during routine GE-CS can predict the possibility of severe underlying OSA. Results The mean age of the patients was 55 years, 74% were men, and 64% had obesity. Severe OSA was diagnosed in 13% of patients with mild UAO (< 50% luminal stenosis), 18% of patients with moderate UAO (50%-75% stenosis), and 45% of patients with severe UAO (> 75% stenosis). The UAO severity was positively correlated with the apnea hypopnea index score (r = 0.305, p = 0.001) and negatively correlated with the minimum SpO2 during GE-CS (r = 0.285, p = 0.023). Logistic regression analysis identified male gender (HR 4.19, p = 0.0267), severe UAO (HR 3.69, p = 0.009), and minimum SpO2 < 90% during GE-CS (HR 3.82, p = 0.008) as an independent predictors of severe OSA. Conclusion Not only the presence of UAO, but also minimum SpO2 < 90% during GE-CS was identified as an independent predictor of severe OSA.
- Open Access
- 13 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115779
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)
- 13 September 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115779
Open AccessAtezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)
- Open Access
- 18 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 203, 108543
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)
- 18 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 203, 108543
Open AccessAtezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)
- 26 March 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (2) , 1-7
Severity of obstructive sleep apnea diagnosed incidentally during gastrointestinal endoscopy under conscious sedation
Background It remains unclear whether patients diagnosed as having obstructive sleep apnea (OSA) incidentally while undergoing gastrointestinal endoscopy under conscious sedation (GE-CS) have predominantly mild disease. Materials and Methods We evaluated differences in the disease characteristics, severity and treatments received between patients who were suspected as having OSA during GE-CS (GE group, n = 56) and patients who visited our hospital with a history of OSA-related symptoms (SY group, n = 123). Results The median age of patients, percentage of men and percentage of patients with obesity were 54 years, 68%, and 21% in the GE group and 51 years, 78%, and 31% in the SY group, respectively. The percentages of patients with mild, moderate, and severe OSA were 18%, 36%, and 43% in the GE group and 30%, 17%, and 39% in the SY group, respectively. The percentages of patients with subjective symptoms (e.g., daytime sleepiness/tiredness, 61% vs. 75%, p = 0.056) and scores on the Epworth sleepiness scale of ≥ 11 (18% vs. 37%, p = 0.009) were lower in the GE group, whereas there was no difference in the proportion of patients with objective symptoms (e.g., loud snoring or apnea, 70% vs. 70%) between the two groups. Patients with moderate-to-severe OSA who received continuous positive airway pressure (CPAP) therapy were fewer in the GE group (34% vs. 65%, p = 0.001). Conclusion A large percentage of patients with OSA diagnosed incidentally while undergoing GE-CS had moderate-to-severe disease but refused CPAP as they often had few subjective symptoms.
- 26 March 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (2) , 1-7
Severity of obstructive sleep apnea diagnosed incidentally during gastrointestinal endoscopy under conscious sedation
Background It remains unclear whether patients diagnosed as having obstructive sleep apnea (OSA) incidentally while undergoing gastrointestinal endoscopy under conscious sedation (GE-CS) have predominantly mild disease. Materials and Methods We evaluated differences in the disease characteristics, severity and treatments received between patients who were suspected as having OSA during GE-CS (GE group, n = 56) and patients who visited our hospital with a history of OSA-related symptoms (SY group, n = 123). Results The median age of patients, percentage of men and percentage of patients with obesity were 54 years, 68%, and 21% in the GE group and 51 years, 78%, and 31% in the SY group, respectively. The percentages of patients with mild, moderate, and severe OSA were 18%, 36%, and 43% in the GE group and 30%, 17%, and 39% in the SY group, respectively. The percentages of patients with subjective symptoms (e.g., daytime sleepiness/tiredness, 61% vs. 75%, p = 0.056) and scores on the Epworth sleepiness scale of ≥ 11 (18% vs. 37%, p = 0.009) were lower in the GE group, whereas there was no difference in the proportion of patients with objective symptoms (e.g., loud snoring or apnea, 70% vs. 70%) between the two groups. Patients with moderate-to-severe OSA who received continuous positive airway pressure (CPAP) therapy were fewer in the GE group (34% vs. 65%, p = 0.001). Conclusion A large percentage of patients with OSA diagnosed incidentally while undergoing GE-CS had moderate-to-severe disease but refused CPAP as they often had few subjective symptoms.
- 22 January 2024
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 47 (5) , 223-227
Feasibility, Tolerability, and Effectiveness of Transbronchial Interventions in Elderly Patients With Malignant Central Airway Obstruction
Background: In elderly patients with malignant central airway obstruction (MCAO), the treating physicians often hesitate to undertake transbronchial interventions (TBIs) as a palliative procedure in view of the advanced age of the patients. Methods: We conducted this retrospective study to evaluate the differences in the feasibility, tolerability, and effectiveness of TBIs between elderly (aged 75 years old or above; elderly group; n=27) and nonelderly (aged below 75 years old; nonelderly group; n=50) patients with MCAO. The primary endpoint was the incidence of complications during (within 24 hours) and after (>24 hours) TBIs. Results: The mean age of the patients was 81 years in the elderly group and 61 years in the nonelderly group. The complications encountered during/after TBI included endobronchial bleeding or hypoxemia requiring intubation occurring during the TBIs, and bacterial pneumonia, airway reocclusion, and stent migration occurring after the TBIs, although there was no difference in the frequency of complications during/after the TBIs between the elderly group and nonelderly group (26% vs. 30%, P=0.706). There was no difference in the percentage of patients in whom successful airway recanalization was achieved by TBI (93% vs. 80%, P=0.197), the percentage of patients who showed symptomatic improvement after the TBIs (67% vs. 76%, P=0.380) and the OS after the TBIs (6.1 vs. 7.3 months, P=0.704) between the 2 groups. Conclusion: TBIs can be undertaken without hesitation as a palliative procedure in elderly patients with MCAO.
- 22 January 2024
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 47 (5) , 223-227
Feasibility, Tolerability, and Effectiveness of Transbronchial Interventions in Elderly Patients With Malignant Central Airway Obstruction
Background: In elderly patients with malignant central airway obstruction (MCAO), the treating physicians often hesitate to undertake transbronchial interventions (TBIs) as a palliative procedure in view of the advanced age of the patients. Methods: We conducted this retrospective study to evaluate the differences in the feasibility, tolerability, and effectiveness of TBIs between elderly (aged 75 years old or above; elderly group; n=27) and nonelderly (aged below 75 years old; nonelderly group; n=50) patients with MCAO. The primary endpoint was the incidence of complications during (within 24 hours) and after (>24 hours) TBIs. Results: The mean age of the patients was 81 years in the elderly group and 61 years in the nonelderly group. The complications encountered during/after TBI included endobronchial bleeding or hypoxemia requiring intubation occurring during the TBIs, and bacterial pneumonia, airway reocclusion, and stent migration occurring after the TBIs, although there was no difference in the frequency of complications during/after the TBIs between the elderly group and nonelderly group (26% vs. 30%, P=0.706). There was no difference in the percentage of patients in whom successful airway recanalization was achieved by TBI (93% vs. 80%, P=0.197), the percentage of patients who showed symptomatic improvement after the TBIs (67% vs. 76%, P=0.380) and the OS after the TBIs (6.1 vs. 7.3 months, P=0.704) between the 2 groups. Conclusion: TBIs can be undertaken without hesitation as a palliative procedure in elderly patients with MCAO.
- Open Access
- 1 December 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 42 (12) , 6113-6119
Overall Survival of Small-cell Lung Cancer Patients With Malignant Central Airway Obstruction Who Received Chemotherapy Without Undergoing Transbronchial Interventions: A Single-institution Retrospective Study
Background/Aim: This study aimed to determine whether the prognosis of small-cell lung cancer (SCLC) patients with malignant central airway obstruction (MCAO) who receive chemotherapy without undergoing transbronchial intervention (TBI) is not inferior to that of SCLC patients without MCAO. Patients and Methods: We compared overall survival (OS) from the time of SCLC diagnosis between stage III or IV SCLC patients with MCAO (MCAO group, n=22) and those without MCAO (non-MCAO group, n=88). MCAO is generally defined as >50% obstruction of the trachea or mainstem bronchi. Results: The median interval from the time of SCLC diagnosis until the initiation of anticancer therapy and the median number of chemotherapy regimens were 6 days and 2 regimens, respectively, in the MCAO group and 15 days and 2 regimens in the non-MCAO group. During the median follow-up period of 11.7 months after SCLC diagnosis, 95% of the patients in the MCAO group and 85% of the patients in the non-MCAO group died. No difference in the median OS (11.9 months vs. 12.4 months, p=0.455) was seen between the MCAO group and the non-MCAO group. A multivariate analysis showed that the presence of MCAO was not associated with an increased risk of death in SCLC patients who received chemotherapy (p=0.664). Conclusion: The prognosis of SCLC patients with MCAO who receive chemotherapy without undergoing TBI is not inferior to that of SCLC patients without MCAO.
- 1 December 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 42 (12) , 6113-6119
Open AccessOverall Survival of Small-cell Lung Cancer Patients With Malignant Central Airway Obstruction Who Received Chemotherapy Without Undergoing Transbronchial Interventions: A Single-institution Retrospective Study
Background/Aim: This study aimed to determine whether the prognosis of small-cell lung cancer (SCLC) patients with malignant central airway obstruction (MCAO) who receive chemotherapy without undergoing transbronchial intervention (TBI) is not inferior to that of SCLC patients without MCAO. Patients and Methods: We compared overall survival (OS) from the time of SCLC diagnosis between stage III or IV SCLC patients with MCAO (MCAO group, n=22) and those without MCAO (non-MCAO group, n=88). MCAO is generally defined as >50% obstruction of the trachea or mainstem bronchi. Results: The median interval from the time of SCLC diagnosis until the initiation of anticancer therapy and the median number of chemotherapy regimens were 6 days and 2 regimens, respectively, in the MCAO group and 15 days and 2 regimens in the non-MCAO group. During the median follow-up period of 11.7 months after SCLC diagnosis, 95% of the patients in the MCAO group and 85% of the patients in the non-MCAO group died. No difference in the median OS (11.9 months vs. 12.4 months, p=0.455) was seen between the MCAO group and the non-MCAO group. A multivariate analysis showed that the presence of MCAO was not associated with an increased risk of death in SCLC patients who received chemotherapy (p=0.664). Conclusion: The prognosis of SCLC patients with MCAO who receive chemotherapy without undergoing TBI is not inferior to that of SCLC patients without MCAO.
- Open Access
- 24 September 2022
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 33, 100642
Prognosis of stage I non-small cell lung cancer patients aged ≥ 80 years who were considered medically operable but received best supportive care alone
- 24 September 2022
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 33, 100642
Open AccessPrognosis of stage I non-small cell lung cancer patients aged ≥ 80 years who were considered medically operable but received best supportive care alone
- 31 May 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 42 (6) , 3125-3131
Difference in the Overall Survival Between Malignant Central Airway Obstruction Patients Treated by Transbronchial Microwave Ablation and Stent Placement: A Single-institution Retrospective Study
Background/Aim: Transbronchial microwave ablation (MWA) can be performed safely in patients with malignant central airway obstruction (MCAO), under moderate sedation and a high fraction of inspired oxygen. Patients and Methods: We retrospectively evaluated the difference in the overall survival (OS) after transbronchial interventions (TBIs) between MCAO patients with endoluminal or mixed-type obstruction who were treated by MWA (MWA group, n=34) and those with extraluminal obstruction who were treated by stent placement (STP) (STP group, n=27). Results: The OS was longer in the MWA group than in the STP group (10.2 months vs. 4.5 months, p=0.001). A significant difference in the OS between the two groups was observed in the patients who received post-TBI anticancer therapy (27.2 months vs. 6.0 months, p=0.002). The OS tended to be longer in the MWA group than in the STP group, among the patients who received best supportive care alone (3.8 months vs. 1.8 months, p=0.068). Nine patients (26%) of the MWA group underwent additional MWA when tumor regrowth into the airway lumen was noted (median of TBI sessions, 3). Multivariate analysis identified the adoption of MWA as the initial treatment procedure to be independently associated with a reduced risk of death in patients with MCAO (hazard ratio=0.473, p=0.031). Conclusion: Adoption of MWA as the initial treatment procedure is beneficial in MCAO patients with endoluminal or mixed-type obstruction, regardless of whether patients receive post-TBI anticancer therapy or not.
- 31 May 2022
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 42 (6) , 3125-3131
Difference in the Overall Survival Between Malignant Central Airway Obstruction Patients Treated by Transbronchial Microwave Ablation and Stent Placement: A Single-institution Retrospective Study
Background/Aim: Transbronchial microwave ablation (MWA) can be performed safely in patients with malignant central airway obstruction (MCAO), under moderate sedation and a high fraction of inspired oxygen. Patients and Methods: We retrospectively evaluated the difference in the overall survival (OS) after transbronchial interventions (TBIs) between MCAO patients with endoluminal or mixed-type obstruction who were treated by MWA (MWA group, n=34) and those with extraluminal obstruction who were treated by stent placement (STP) (STP group, n=27). Results: The OS was longer in the MWA group than in the STP group (10.2 months vs. 4.5 months, p=0.001). A significant difference in the OS between the two groups was observed in the patients who received post-TBI anticancer therapy (27.2 months vs. 6.0 months, p=0.002). The OS tended to be longer in the MWA group than in the STP group, among the patients who received best supportive care alone (3.8 months vs. 1.8 months, p=0.068). Nine patients (26%) of the MWA group underwent additional MWA when tumor regrowth into the airway lumen was noted (median of TBI sessions, 3). Multivariate analysis identified the adoption of MWA as the initial treatment procedure to be independently associated with a reduced risk of death in patients with MCAO (hazard ratio=0.473, p=0.031). Conclusion: Adoption of MWA as the initial treatment procedure is beneficial in MCAO patients with endoluminal or mixed-type obstruction, regardless of whether patients receive post-TBI anticancer therapy or not.
- Open Access
- 18 October 2021
- Published by Springer Nature in Research Square
Ablative Procedures and Additional Anticancer Therapy Prolong the Survival in Patients With Endoluminal or Mixed-type Malignant Central Airway Obstruction: A Single-institution Retrospective Study
BackgroundIn patients with malignant central airway obstruction (MCAO) receiving transbronchial interventions (TBIs), it remains unclear if the prognosis after the intervention might differ according to the bronchoscopic appearance of the airway obstruction. MethodsTBIs were undertaken in MCAO patients with endoluminal obstruction (TM group, n = 19), extraluminal obstruction (EX group, n = 19) and mixed-type obstruction (MX group, n = 23), under moderate sedation and high fractions of inspired oxygen (FiO2). We evaluated the differences in the overall survival period (OS) after the TBIs among the 3 groups. ResultsRegarding the TBIs, the initial procedure was transbronchial microwave ablation (TMA) in the TM group and MX group and stent placement in the EX group. However, 7 patients in the MX group received stent placement as the second-line procedure, after failure of TMA. The OS tended to be longer in the TM/MX group as compared to that in the EX group, both in the subgroups of patients who received post-TBI anticancer therapy (27.2 months/32.9 months vs. 6.0 months, p = 0.011) and in the subgroups of patients who received best supportive care alone (3.2 months/3.1 months vs. 1.4 months, p = 0.072). Multivariate analysis identified adoption of TMA as the initial procedure, successful airway patency restoration following the TBI, and post-TBI anticancer therapy as independent factors associated with a reduced risk of death in patients with MCAO. ConclusionIt is beneficial to administer post-TBI anticancer therapy to MCAO patients with endoluminal or mixed-type obstruction following ablative procedures.
- 18 October 2021
- Published by Springer Nature in Research Square
Open AccessAblative Procedures and Additional Anticancer Therapy Prolong the Survival in Patients With Endoluminal or Mixed-type Malignant Central Airway Obstruction: A Single-institution Retrospective Study
BackgroundIn patients with malignant central airway obstruction (MCAO) receiving transbronchial interventions (TBIs), it remains unclear if the prognosis after the intervention might differ according to the bronchoscopic appearance of the airway obstruction. MethodsTBIs were undertaken in MCAO patients with endoluminal obstruction (TM group, n = 19), extraluminal obstruction (EX group, n = 19) and mixed-type obstruction (MX group, n = 23), under moderate sedation and high fractions of inspired oxygen (FiO2). We evaluated the differences in the overall survival period (OS) after the TBIs among the 3 groups. ResultsRegarding the TBIs, the initial procedure was transbronchial microwave ablation (TMA) in the TM group and MX group and stent placement in the EX group. However, 7 patients in the MX group received stent placement as the second-line procedure, after failure of TMA. The OS tended to be longer in the TM/MX group as compared to that in the EX group, both in the subgroups of patients who received post-TBI anticancer therapy (27.2 months/32.9 months vs. 6.0 months, p = 0.011) and in the subgroups of patients who received best supportive care alone (3.2 months/3.1 months vs. 1.4 months, p = 0.072). Multivariate analysis identified adoption of TMA as the initial procedure, successful airway patency restoration following the TBI, and post-TBI anticancer therapy as independent factors associated with a reduced risk of death in patients with MCAO. ConclusionIt is beneficial to administer post-TBI anticancer therapy to MCAO patients with endoluminal or mixed-type obstruction following ablative procedures.